318 related articles for article (PubMed ID: 30987862)
1. Immune checkpoint molecule herpes virus entry mediator is overexpressed and associated with poor prognosis in human glioblastoma.
Han MZ; Wang S; Zhao WB; Ni SL; Yang N; Kong Y; Huang B; Chen AJ; Li XG; Wang J; Wang DH
EBioMedicine; 2019 May; 43():159-170. PubMed ID: 30987862
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of herpesvirus entry mediator expression in human hepatocellular carcinoma.
Hokuto D; Sho M; Yamato I; Yasuda S; Obara S; Nomi T; Nakajima Y
Eur J Cancer; 2015 Jan; 51(2):157-65. PubMed ID: 25468715
[TBL] [Abstract][Full Text] [Related]
3. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
4. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
[TBL] [Abstract][Full Text] [Related]
5. Clinical characterization, genetic profiling, and immune infiltration of TOX in diffuse gliomas.
Zhang H; Fan F; Yu Y; Wang Z; Liu F; Dai Z; Zhang L; Liu Z; Cheng Q
J Transl Med; 2020 Aug; 18(1):305. PubMed ID: 32762688
[TBL] [Abstract][Full Text] [Related]
6. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Landscape of Tumor-Infiltrating Immune Cells and Immune Checkpoints in Glioblastoma.
Wu S; Yang W; Zhang H; Ren Y; Fang Z; Yuan C; Yao Z
Technol Cancer Res Treat; 2019 Jan; 18():1533033819869949. PubMed ID: 31451090
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
Patil V; Mahalingam K
Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
[TBL] [Abstract][Full Text] [Related]
9. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
[TBL] [Abstract][Full Text] [Related]
10. Expression and Clinical Significance of Herpes Virus Entry Mediator (HVEM) in Breast Cancer.
Tsang JYS; Chan KW; Ni YB; Hlaing T; Hu J; Chan SK; Cheung SY; Tse GM
Ann Surg Oncol; 2017 Dec; 24(13):4042-4050. PubMed ID: 28612127
[TBL] [Abstract][Full Text] [Related]
11. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.
Close HJ; Stead LF; Nsengimana J; Reilly KA; Droop A; Wurdak H; Mathew RK; Corns R; Newton-Bishop J; Melcher AA; Short SC; Cook GP; Wilson EB
Clin Exp Immunol; 2020 Apr; 200(1):33-44. PubMed ID: 31784984
[TBL] [Abstract][Full Text] [Related]
13. Identification of Immune-Related Genes Contributing to the Development of Glioblastoma Using Weighted Gene Co-expression Network Analysis.
Kong Y; Feng ZC; Zhang YL; Liu XF; Ma Y; Zhao ZM; Huang B; Chen AJ; Zhang D; Thorsen F; Wang J; Yang N; Li XG
Front Immunol; 2020; 11():1281. PubMed ID: 32765489
[No Abstract] [Full Text] [Related]
14. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment.
Jia D; Li S; Li D; Xue H; Yang D; Liu Y
Aging (Albany NY); 2018 Apr; 10(4):592-605. PubMed ID: 29676997
[TBL] [Abstract][Full Text] [Related]
15. Significant involvement of herpesvirus entry mediator in human esophageal squamous cell carcinoma.
Migita K; Sho M; Shimada K; Yasuda S; Yamato I; Takayama T; Matsumoto S; Wakatsuki K; Hotta K; Tanaka T; Ito M; Konishi N; Nakajima Y
Cancer; 2014 Mar; 120(6):808-17. PubMed ID: 24249528
[TBL] [Abstract][Full Text] [Related]
16. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
Zhang B; Shen R; Cheng S; Feng L
Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
[TBL] [Abstract][Full Text] [Related]
17. B2M overexpression correlates with malignancy and immune signatures in human gliomas.
Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K
Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560
[TBL] [Abstract][Full Text] [Related]
18. A novel immune cell signature for predicting glioblastoma after radiotherapy prognosis and guiding therapy.
Huang R; Lu X; Sun X; Wu H
Int J Immunopathol Pharmacol; 2024; 38():3946320241249395. PubMed ID: 38687369
[No Abstract] [Full Text] [Related]
19. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
20. RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML.
Lichtenegger FS; Kondla I; Krempasky M; Weber AL; Herold T; Krupka C; Spiekermann K; Schneider S; Büchner T; Berdel WE; Wörmann BJ; Hiddemann W; Subklewe M
Cancer Immunol Immunother; 2015 Dec; 64(12):1505-15. PubMed ID: 26377688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
